SecProbe.io

CORRESP
1
filename1.htm

        Seaport West

        155 Seaport Boulevard

        Boston, MA 02210-2600

        617 832 1000 main

        617 832 7000 fax

    November 24, 2015

        Gabrielle A. Bernstein

        617 832 1161 direct

        gbernstein@foleyhoag.com

    VIA EDGAR

        Securities and Exchange Commission

        Division of Corporate Finance

        100 F Street, N.E.

        Washington, DC 20549

    Re:

        Cellectar Biosciences, Inc. (CIK 0001279704)

        Registration Statement on Form S-3

Ladies and Gentlemen:

This letter constitutes supplemental correspondence
on behalf of Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), related to and filed together with
the Company’s Registration Statement on Form S-3 (the “Registration Statement”). The Registration Statement covers
the resale by the selling stockholders identified therein (the “Selling Stockholders”) of up to 1,500,000 shares of
the Company’s common stock, $0.00001 par value per share (“Common Stock”), issuable upon exercise of outstanding
warrants to purchase Common Stock (the “Warrants”). The Warrants were issued in a private placement which closed on
October 1, 2015. The Company was required to file this Registration Statement within 60 days after October 1, 2015 pursuant to
a registration rights agreement with the Selling Stockholders, even though the Warrants will not become exercisable until April
1, 2016.

Please direct any communications concerning
the Registration Statement to Paul Bork at (617) 832-1113, email—pbork@foleyhoag.com, or, in his absence, Daniel Clevenger
at (617) 832-1283, email—dclevenger@foleyhoag.com, or me at the telephone number and email address set forth above.

Sincerely,

/s/	Gabrielle
A. Bernstein

Gabrielle A. Bernstein

 cc: Paul Bork, Esq.

Daniel Clevenger, Esq.